MedTrace Logo

A Study Based on the French National Health Insurance Database in Participants With Psychotic Disorders

NCT05633108 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 579728

Last updated 2023-11-18

No results posted yet for this study

Summary

The primary purpose of the study is to compare therapy with antipsychotic medication (antipsychotic monotherapy or antipsychotic combination) versus no antipsychotic medication, and antipsychotic monotherapy versus antipsychotic combination, regarding time to psychiatric rehospitalization, in participants with a psychotic disorder (that is, schizophrenia, schizotypal disorders, schizoaffective disorders, persistent or acute or induced or non-organic delusional disorders, recurrent depressive disorder with psychotic symptoms).

Conditions

  • Psychotic Disorders

Interventions

OTHER

No Intervention

No intervention will be administered.

Sponsors & Collaborators

  • Eisai Co., Ltd.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-30
Primary Completion
2023-09-30
Completion
2023-09-30
FDA Drug
Yes

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05633108 on ClinicalTrials.gov